EASL 2015 HCV Vaccine Lecture: Dr T. Baumert
Posted on April 29, 2015
Please click here to view this important EASL 2015 HCV presentation by Thomas F. Baumert, MD.
Thomas F. Baumert, MD is Professor of Medicine, head of Inserm Research Unit U1110, Institute of Viral and Liver Diseases, head of the Laboratory of Excellence HEPSYS at the University of Strasbourg and Physician at the Center for Digestive Disease and Hepatology at the Strasbourg University Hospitals.
He received his MD from the University of Heidelberg, Germany. Following his doctoral thesis at the German Cancer Research Center (DKFZ) in Heidelberg (headed at that time by Nobel laureate Prof. H. zur Hausen) and his internship in Internal Medicine at the Ludwig Maximilians University in Munich, he was a postdoctoral fellow in Dr. T. J. Liang’s laboratory at the Dept. of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston and the Liver Diseases Branch at the National Institutes of Health, Bethesda,USA. He subsequently joined the Department of Medicine at the University Hospital in Freiburg, Germany to become a board-certified internist and gastroenterologist, associate professor and to establish his laboratory focussing on the molecular pathogenesis of hepatitis B and C virus infection. In 2006, he relocated to the University of Strasbourg in France as full professor of medicine to create and head a new Inserm research unit on virus-host interactions and liver disease and establish a highly recognized program on translational virology and hepatology. Most recently he spent a sabbatical as a research scholar at Mass General Hospital, the BROAD institute and Harvard Medical School, Boston.His laboratory focuses on the modelling and discovery of the biological circuits underlying viral persistence and virus-induced disease such as chronic inflammation and cancer. As a model he uses chronic hepatitis B and C virus infection – a major cause of chronic liver disease and cancer world-wide. The understanding of the molecular mechanisms of virus-host interactions and disease biology has allowed his laboratory to uncover novel strategies for prevention and treatment of chronic viral hepatitis. He has received several awards including the Hans Popper Young Investigator Award, the Chair of Excellence and Laboratory of Excellence Awards of the French National Research Agency and the Infectious Disease Award of the German Infectious Disease Society. Most recently he has been awarded the Prix Galien (2013) for the discovery of host-targeting entry inhibitors as a novel strategy for prevention and treatment of HCV infection. He has published more than 150 scientific articles including Nature Medicine, N. Engl. J. Med., Cell Host & Microbe, PNAS, J. Clin. Invest. and J. Exp. Med.. He is an inventor on 11 patents and patent applications and scientific founder of Vironexx, a biotech company focussing on discovery and preclinical development of host-targeting antivirals. In his translational work he focuses on novel approaches for prevention and treatment of virus-induced liver disease. Research in his laboratory is supported by the European Commission through the ERC, FP7 and INTERREG IV programs, Inserm, the Agence Nationale de Recherches sur le Sida, hépatites virales B et C (ANRS) and the Agence Nationale de Recherche (ANR), France as well as industry. He is an Associate Editor for the Journal of Hepatology (IF 9.8) and serves as a member of the editorial board of several journals in the field of Hepatology and Virology. He actively participates in structuring national and international research programs in Virology and Hepatology by serving as on various review and policy committees at the European Association for the Study of Liver Disease (EASL) as well as Inserm, CNRS, and ANRS France (ATIP-AVENIR).